Section
A nationwide retrospective cohort (36,129 patients) found antibiotic use before or during biologic treatment for psoriasis was associated with higher risk of discontinuation or switch; multiple dispensations carried larger risk, suggesting
A double‑blind RCT in 160 healthy adults found that intranasal oxytocin combined with structured positive interaction and daily physical intimacy (affectionate touch, sex) was associated with reduced cortisol and modestly faster dermatologi
The randomized MATISSE trial shows neoadjuvant nivolumab ± low‑dose ipilimumab yields high major/partial pathological response rates, excellent 2‑year disease‑specific survival, and enables organ preservation in many patients with resectabl
A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable sh
A large FAERS analysis links immune checkpoint inhibitors (ICIs) to markedly increased SJS/TEN risk, demonstrates additive synergy with high‑risk small molecules, and shows delayed latency particularly with anti–PD‑1 agents — supporting a t
Icotrokinra, an oral peptide that selectively blocks the IL‑23 receptor, produced substantial skin clearance (IGA 0/1 65–70%, PASI 90 50–57% at week 16) versus placebo in phase 3 trials, with broadly similar short‑term safety to placebo and
Interim results from the multicentre phase 3 TRIM trial show no survival benefit from adding scheduled whole‑body CT or FDG‑PET‑CT to physical‑examination follow‑up after radical surgery for stage IIB–C and III cutaneous melanoma at median
A nationwide Taiwanese active-comparator cohort found SGLT2 inhibitor use was associated with a lower incidence of new-onset atopic dermatitis compared with DPP‑4 inhibitors; the effect persisted across sensitivity analyses, showed a dose-r
A Taiwanese nationwide cohort study found SGLT2 inhibitor use linked to a lower incidence of new-onset atopic dermatitis versus DPP4 inhibitors (IPTW-adjusted HR 0.847), with a dose-response effect and stronger protection in men.
A phase II trial evaluating rilzabrutinib, a BTK inhibitor, in moderate-to-severe atopic dermatitis showed no significant improvement in primary endpoints but demonstrated rapid itch relief and a favorable safety profile.
This living systematic review and network meta-analysis evaluates efficacy, safety, and tolerability of medical treatments for moderate to severe hidradenitis suppurativa, highlighting top-performing agents and informing clinical decision-m
Two brothers with lamellar ichthyosis presented with enamel defects and dental caries; dental rehabilitation with preventive measures was completed alongside dermatologic care.
This study evaluates whether a single application of hydrocolloid dressing improves scar appearance and reduces complications compared to daily petroleum ointment after dermatologic excisions.
The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.
This clinical trial compares the effectiveness and safety of hydrocolloid dressings versus petroleum ointment in post-surgical scar healing, emphasizing patient comfort and cosmetic outcomes.
This study identifies specific T-cell receptor clonotypes associated with aggressive subtypes and poorer survival in mycosis fungoides and Sézary syndrome, supporting TCR sequencing as a tool for refined risk stratification in cutaneous T-c
The phase 3 BRAVE-AA-PEDS trial demonstrates that baricitinib, a JAK inhibitor, significantly restores scalp, eyebrow, and eyelash hair in adolescents with severe alopecia areata, achieving up to 80% hair regrowth in recent-onset cases afte
The MERLIN_001 study validates a combined clinicopathological and gene expression profile test that accurately predicts sentinel lymph node metastasis risk in patients with cutaneous melanoma, potentially guiding safer, more personalized su
Despite advances in antiretroviral therapy, dermatologic diseases remain prevalent in people with HIV, with incidence declining yet significant disparities persisting related to immune status, demographics, and structural factors.
A retrospective cohort study demonstrates that implementation of KP-SUNTRAC increases targeted skin cancer screening and detection among high-risk solid organ transplant recipients without increasing health care utilization.
